Floatz logo

Tas-102

Recurrent Primary Peritoneal Cavity Cancer

National Cancer Institute (NCI)unclassifiedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Primary Peritoneal Cavity Cancer cohort.

Asset / SponsorPhaseRating
Metformin
University of Chicago
Phase 2BB
Alvac-Ny-Eso-1 /Tricom Vaccine
Roswell Park Cancer Institute
Phase 1/2B
Flavopiridol
National Cancer Institute (NCI)
Phase 2B
SJG 136
National Cancer Institute (NCI)
Phase 2CC
Auranofin
Mayo Clinic
Early Phase 1CC
AFP-464
National Cancer Institute (NCI)
Phase 1C

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →